Fifth Third Bancorp Has $150,000 Stock Position in Natera, Inc. (NASDAQ:NTRA)

Fifth Third Bancorp decreased its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 81.1% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,064 shares of the medical research company's stock after selling 4,565 shares during the period. Fifth Third Bancorp's holdings in Natera were worth $150,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of NTRA. LRI Investments LLC acquired a new stake in Natera during the 4th quarter worth approximately $29,000. Blue Trust Inc. lifted its holdings in shares of Natera by 223.7% during the 4th quarter. Blue Trust Inc. now owns 301 shares of the medical research company's stock valued at $48,000 after acquiring an additional 208 shares in the last quarter. EverSource Wealth Advisors LLC lifted its holdings in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after acquiring an additional 261 shares in the last quarter. Principal Securities Inc. boosted its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its holdings in Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company's stock.

Natera Price Performance

Shares of Natera stock traded up $0.88 on Friday, hitting $171.86. 1,516,357 shares of the company's stock traded hands, compared to its average volume of 1,415,257. The firm's 50-day moving average price is $156.53 and its two-hundred day moving average price is $158.62. The stock has a market capitalization of $23.47 billion, a PE ratio of -116.91 and a beta of 1.74. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The firm had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. During the same quarter in the previous year, the company earned ($0.56) earnings per share. The business's revenue for the quarter was up 36.5% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other news, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction dated Tuesday, June 10th. The shares were sold at an average price of $164.44, for a total value of $657,760.00. Following the completion of the transaction, the director now owns 5,704 shares of the company's stock, valued at $937,965.76. This trade represents a 41.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Steven Leonard Chapman sold 9,563 shares of the business's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $1,323,614.83. Following the transaction, the chief executive officer now directly owns 212,541 shares in the company, valued at $29,417,799.81. The trade was a 4.31% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 59,755 shares of company stock worth $8,898,589. Corporate insiders own 7.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Piper Sandler increased their target price on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research note on Thursday, May 15th. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Robert W. Baird boosted their target price on shares of Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Canaccord Genuity Group restated a "buy" rating and issued a $180.00 target price on shares of Natera in a research note on Wednesday, February 26th. Finally, UBS Group lifted their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a research note on Friday, May 9th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.